244 related articles for article (PubMed ID: 19211644)
21. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
22. Modified chop-chemotherapy plus rituximab for diffuse large b-cell lymphoma complicating ataxia-telangiectasia.
Rossi G; Zecca M; Marchi A; de Stefano P; Sammarchi L; Locatelli F
Br J Haematol; 2003 Jan; 120(2):369-71. PubMed ID: 12542504
[No Abstract] [Full Text] [Related]
23. Concurrent administration of rituximab and CHOP chemotherapeutic agents for outpatients with CD20-positive lymphoma.
Yakushijin Y; Tatsukawa T; Yamaguchi T; Egawa T; Hidaka N; Ido K; Suemaru K; Yasukawa M; Araki H
Anticancer Agents Med Chem; 2012 Sep; 12(7):829-34. PubMed ID: 22721383
[TBL] [Abstract][Full Text] [Related]
24. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.
Vitolo U; Trněný M; Belada D; Burke JM; Carella AM; Chua N; Abrisqueta P; Demeter J; Flinn I; Hong X; Kim WS; Pinto A; Shi YK; Tatsumi Y; Oestergaard MZ; Wenger M; Fingerle-Rowson G; Catalani O; Nielsen T; Martelli M; Sehn LH
J Clin Oncol; 2017 Nov; 35(31):3529-3537. PubMed ID: 28796588
[TBL] [Abstract][Full Text] [Related]
25. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
[TBL] [Abstract][Full Text] [Related]
26. Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma.
Rushton CK; Arthur SE; Alcaide M; Cheung M; Jiang A; Coyle KM; Cleary KLS; Thomas N; Hilton LK; Michaud N; Daigle S; Davidson J; Bushell K; Yu S; Rys RN; Jain M; Shepherd L; Marra MA; Kuruvilla J; Crump M; Mann K; Assouline S; Connors JM; Steidl C; Cragg MS; Scott DW; Johnson NA; Morin RD
Blood Adv; 2020 Jul; 4(13):2886-2898. PubMed ID: 32589730
[TBL] [Abstract][Full Text] [Related]
27. Rituximab in heavily pretreated cutaneous B-cell lymphoma.
Zinzani PL; Stefoni V; Alinari L; Vianelli N; Baccarani M
Leuk Lymphoma; 2003 Sep; 44(9):1637-8. PubMed ID: 14565673
[No Abstract] [Full Text] [Related]
28. Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma.
Lee GW; Go SI; Kim SH; Hong J; Kim YR; Oh S; Kim SY; Do YR; Lee H; Lee SI; Bae SH; Oh SY; Song MK; Lee WS; Lee B; Kim JS; Kim MK; Kang HJ; Ahn JS; Yhim HY; Kim HJ; Kim SJ; Kim WS; Suh C;
Leuk Lymphoma; 2015 Apr; 56(4):1020-6. PubMed ID: 25039351
[TBL] [Abstract][Full Text] [Related]
29. Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab.
Hiraga J; Tomita A; Suzuki N; Takagi Y; Narita M; Kagami Y
Ann Hematol; 2018 Nov; 97(11):2253-2255. PubMed ID: 29725760
[No Abstract] [Full Text] [Related]
30. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.
Kim DH; Jung HD; Kim JG; Lee JJ; Yang DH; Park YH; Do YR; Shin HJ; Kim MK; Hyun MS; Sohn SK
Blood; 2006 Oct; 108(8):2720-5. PubMed ID: 16609067
[TBL] [Abstract][Full Text] [Related]
31. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma.
Coiffier B
Semin Oncol; 2002 Apr; 29(2 Suppl 6):18-22. PubMed ID: 12040530
[TBL] [Abstract][Full Text] [Related]
32. CD20-positive primary gastric T-cell lymphoma poorly responding to initial treatment with rituximab plus CHOP, and a literature review.
Kakinoki Y; Hashiguchi J; Ishio T; Chiba K; Niino D; Ohshima K
Int J Hematol; 2015 Dec; 102(6):702-8. PubMed ID: 26251099
[TBL] [Abstract][Full Text] [Related]
33. FcgammaRIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP).
Camilleri-Broët S; Mounier N; Delmer A; Brière J; Casasnovas O; Cassard L; Gaulard P; Christian B; Coiffier B; Sautès-Fridman C
Leukemia; 2004 Dec; 18(12):2038-40. PubMed ID: 15470484
[No Abstract] [Full Text] [Related]
34. [Recent progress in rituximab therapy and its resistance--how do we overcome?].
Hatake K; Yokoyama M; Terui Y
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1177-82. PubMed ID: 17687198
[TBL] [Abstract][Full Text] [Related]
35. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
[TBL] [Abstract][Full Text] [Related]
36. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
[TBL] [Abstract][Full Text] [Related]
37. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
38. Aggressive lymphoma: improving treatment outcome with rituximab.
Coiffier B; Pfreundschuh M; Stahel R; Vose J; Zinzani PL
Anticancer Drugs; 2002 Nov; 13 Suppl 2():S43-50. PubMed ID: 12710590
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
40. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
Dai MS; Chao TY; Kao WY; Shyu RY; Liu TM
Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]